Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.
Tumors in any part of the heart. They include primary cardiac tumors and metastatic tumors to the heart. Their interference with normal cardiac functions can cause a wide variety of symptoms including HEART FAILURE; CARDIAC ARRHYTHMIAS; or EMBOLISM.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Tumors or cancer of the COLON.
Cancer or tumors of the MAXILLA or upper jaw.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Tumors or cancer of the anal gland.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Neoplasms composed of fatty tissue or connective tissue made up of fat cells in a meshwork of areolar tissue. The concept does not refer to neoplasms located in adipose tissue.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
Tumors or cancer of the DUODENUM.
Tumors or cancers of the ADRENAL CORTEX.
Tumors or cancer of the MOUTH.
Tumors or cancer of the MEDIASTINUM.
Tumors or cancer of the TONGUE.
Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL).
Tumors or cancer of the STOMACH.
Tumors or cancer of the URINARY BLADDER.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.
Tumors or cancer of the VAGINA.
A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tumors or cancer located in muscle tissue or specific muscles. They are differentiated from NEOPLASMS, MUSCLE TISSUE which are neoplasms composed of skeletal, cardiac, or smooth muscle tissue, such as MYOSARCOMA or LEIOMYOMA.
Experimentally induced tumors of the LIVER.
A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
A malignant epithelial tumor with a glandular organization.
Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.
Surgical removal of the pancreas. (Dorland, 28th ed)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Tumors or cancer of the PARANASAL SINUSES.
Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.
Tumors or cancer of the human BREAST.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
Neoplasms of the bony orbit and contents except the eyeball.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
A benign tumor composed of fat cells (ADIPOCYTES). It can be surrounded by a thin layer of connective tissue (encapsulated), or diffuse without the capsule.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc.
Tumors or cancer of the BRONCHI.
Tumors or cancer of the PERITONEUM.
Distinctive neoplastic disorders of histiocytes. Included are malignant neoplasms of MACROPHAGES and DENDRITIC CELLS.
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.
Neoplasms of the bony part of the skull.
Tumors or cancer of the VULVA.
Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)
Tumors or cancer of any part of the hearing and equilibrium system of the body (the EXTERNAL EAR, the MIDDLE EAR, and the INNER EAR).
Tumors or cancer of the LIP.
A benign tumor of fibrous or fully developed connective tissue.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Tumors or cancer of the ADRENAL GLANDS.
Tumors or cancer of the pelvic region.
Tumors or cancer of the gallbladder.
The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.
Neoplasms composed of fibrous and epithelial tissue. The concept does not refer to neoplasms located in fibrous tissue or epithelium.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Neoplasms composed of connective tissue, including elastic, mucous, reticular, osseous, and cartilaginous tissue. The concept does not refer to neoplasms located in connective tissue.
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
RNA present in neoplastic tissue.
Trophoblastic growth, which may be gestational or nongestational in origin. Trophoblastic neoplasia resulting from pregnancy is often described as gestational trophoblastic disease to distinguish it from germ cell tumors which frequently show trophoblastic elements, and from the trophoblastic differentiation which sometimes occurs in a wide variety of epithelial cancers. Gestational trophoblastic growth has several forms, including HYDATIDIFORM MOLE and CHORIOCARCINOMA. (From Holland et al., Cancer Medicine, 3d ed, p1691)
A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000)
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Diseases of rodents of the order RODENTIA. This term includes diseases of Sciuridae (squirrels), Geomyidae (gophers), Heteromyidae (pouched mice), Castoridae (beavers), Cricetidae (rats and mice), Muridae (Old World rats and mice), Erethizontidae (porcupines), and Caviidae (guinea pigs).
Tumors or cancer of the CECUM.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
A neoplasm derived from blood vessels, characterized by numerous prominent endothelial cells that occur singly, in aggregates, and as the lining of congeries of vascular tubes or channels. Hemangioendotheliomas are relatively rare and are of intermediate malignancy (between benign hemangiomas and conventional angiosarcomas). They affect men and women about equally and rarely develop in childhood. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)
Tumors or cancer of the DIGESTIVE SYSTEM.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer in the JEJUNUM region of the small intestine (INTESTINE, SMALL).
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Using fine needles (finer than 22-gauge) to remove tissue or fluid specimens from the living body for examination in the pathology laboratory and for disease diagnosis.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
Liquid material found in epithelial-lined closed cavities or sacs.
Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included.
A benign epithelial tumor of the LIVER.
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Malignant neoplasms composed of MACROPHAGES or DENDRITIC CELLS. Most histiocytic sarcomas present as localized tumor masses without a leukemic phase. Though the biological behavior of these neoplasms resemble lymphomas, their cell lineage is histiocytic not lymphoid.
A benign, non-neoplastic, usually self-limiting epithelial lesion closely resembling squamous cell carcinoma clinically and histopathologically. It occurs in solitary, multiple, and eruptive forms. The solitary and multiple forms occur on sunlight exposed areas and are identical histologically; they affect primarily white males. The eruptive form usually involves both sexes and appears as a generalized papular eruption.
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Tests to experimentally measure the tumor-producing/cancer cell-producing potency of an agent by administering the agent (e.g., benzanthracenes) and observing the quantity of tumors or the cell transformation developed over a given period of time. The carcinogenicity value is usually measured as milligrams of agent administered per tumor developed. Though this test differs from the DNA-repair and bacterial microsome MUTAGENICITY TESTS, researchers often attempt to correlate the finding of carcinogenicity values and mutagenicity values.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Tumor or cancer of the MALE GENITALIA.
Intracranial tumors originating in the region of the brain inferior to the tentorium cerebelli, which contains the cerebellum, fourth ventricle, cerebellopontine angle, brain stem, and related structures. Primary tumors of this region are more frequent in children, and may present with ATAXIA; CRANIAL NERVE DISEASES; vomiting; HEADACHE; HYDROCEPHALUS; or other signs of neurologic dysfunction. Relatively frequent histologic subtypes include TERATOMA; MEDULLOBLASTOMA; GLIOBLASTOMA; ASTROCYTOMA; EPENDYMOMA; CRANIOPHARYNGIOMA; and choroid plexus papilloma (PAPILLOMA, CHOROID PLEXUS).
Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.
Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
A family of mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells. These cells do not have a normal anatomic homolog. (From Fletcher CDM, et. al., World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Soft Tissue and Bone, 2002).
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A mixed mesenchymal tumor composed of two or more mesodermal cellular elements not commonly associated, not counting fibrous tissue as one of the elements. Mesenchymomas are widely distributed in the body and about 75% are malignant. (Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1866)
Tumors or cancer of the RECTUM.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Tumors or cancer of the ESOPHAGUS.
Diseases of the domestic cat (Felis catus or F. domesticus). This term does not include diseases of the so-called big cats such as CHEETAHS; LIONS; tigers, cougars, panthers, leopards, and other Felidae for which the heading CARNIVORA is used.
Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).
A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A usually benign tumor made up predominantly of myoepithelial cells.
Tumors or cancer of the PROSTATE.
Tumors of cancer of the EYELIDS.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
Benign and malignant tumors of the HYPOTHALAMUS. Pilocytic astrocytomas and hamartomas are relatively frequent histologic types. Neoplasms of the hypothalamus frequently originate from adjacent structures, including the OPTIC CHIASM, optic nerve (see OPTIC NERVE NEOPLASMS), and pituitary gland (see PITUITARY NEOPLASMS). Relatively frequent clinical manifestations include visual loss, developmental delay, macrocephaly, and precocious puberty. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2051)
A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.

Specific receptors for glucocorticoid in the cytoplasm of the liver of AH 130 tumor-bearing rats. (1/8373)

Specific receptors for dexamethasone (11beta, 17alpha, 21-trihydroxy-9alpha-fluoro-16alpha-methyl-1,4-pregnadiene-3,20-dione) in the cytoplasm of the liver from AH 130 (solid type) tumor-bearing rats markedly increased in the advanced stage of tumor growth. The cytoplasmic receptors of the livers of normal and tumor-bearing rats differed in their affinities for dexamethasone, and their apparent equilibrium (dissociation) constants (K) for dexamethasone were 4.0 and 2.6 X 10(-9) M, respectively. The rates of dissociation of dexamethasone-receptor complexes and the heat denaturations of the receptors in the livers of normal and tumor-bearing rats were similar. The glucocorticoid receptors of tumor-bearing rat liver had slightly higher affinities than did those of normal liver for all the steroids tested. Only a trace amount of receptors for dexamethasone could be detected in the cytoplasm of AH 130 ascites cells.  (+info)

Differences in benzo(a)pyrene metabolism between rodent liver microsomes and embryonic cells. (2/8373)

Differences in benzo(a)pyrene metabolite pattern have been shown by rodent liver microsomes (Sprague-Dawley) and rodent embryo cells from Syrian hamsters and NIH Swiss mice. Rodent liver induced by methylcholanthrene shows marked quantitative variation between species. Additional pattern changes were found in mouse and hamster embryo secondary cultures with a reduction of the K-region metabolites and a marked increase in 9-hydroxybenzo(a)-pyrene. These results are indicative of a region-specific attack on the carcinogen by the cell monooxygenases which is distinct from the liver attack of microsomal enzymes on benzo(a)pyrene. These results suggest that activation and detoxification of benzo(a)pyrene may be species and tissue variable, and susceptibility and resistence to malignant transformation may be predicted on induction of a fortuitous combination of intermediate metabolic steps.  (+info)

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats. (3/8373)

Three transitional cell carcinomas induced in Fischer 344 rats by a methylcholanthrene pellet or a foreign body inserted locally into the bladder have been serially transplanted in the syngeneic strain for up to 6.5 years. There have been no changes in the individual morphological characteristics of the tumors during this time. Cells cultured in vitro for varying numbers of passages reproduce regularly the morphology of each tumor when they are injected back into the animals and results from a microcytotoxicity assay for cellular immunity indicate that they retain a common, bladder tumor-specific antigen. These tumors are useful for research in turmo biology and are offered to other scientists seeking transplantable carcinomas for experimentation.  (+info)

Ambiguity of the thymidine index. (4/8373)

The observed thymidine indices of seven experimental tumor lines are compared as a function of duration of emulsion exposure. The effects of dose level of tritiated thymidine and background threshold are also evaluated. The results indicate that an arbitrary high background threshold discriminates against "lightly" labeled cells at short periods of exposure but that the chosen threshold becomes less critical with longer exposure. The observed thymidine index increases with increasing duration of emulsion exposure but appears to approach a plateau for all tumor systems. The "thymidine index curves" are significantly different for each tumor. There is an inverse relationship between the dose of tritiated thymidine and the duration of exposure required to recognize the same fraction of cells as labeled in a given tumor. Similar experimental conditions do not necessarily guarantee a valid basis for comparison of observed thymidine indices among tumors.  (+info)

Carcinogenicity of triethanolamine in mice and its mutagenicity after reaction with sodium nitrite in bacteria. (5/8373)

Mice fed a diet containing 0.3 or 0.03% triethanolamine developed malignant tumors. Females showed a high incidence of tumors in lymphoid tissues, while this type was absent in males. Tumors in other tissues were produced at a considerable rate in both sexes, but no hepatoma was found. Triethanolamine was not mutagenic to Bacillus subtilis by itself, but it became mutagenic after reacting with sodium nitrite under acidic conditions or when the mixture was heated. Although N-nitrosodiethanolamine, a known carcinogen and mutagen, was detected in the reaction mixture by thin-layer chromatography, it may not be the main mutagenic product, because the product was a stable and direct mutagen and its mutagenic activity was destroyed by liver enzymes, unlike N-nitrosodiethanolamine. The lethal and mutagenic DNA damages produced by this unidentified product were susceptible to some extent to the repair functions of the bacteria.  (+info)

Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). (6/8373)

Fas ligand is a type II transmembrane protein which can induce apoptosis in Fas-expressing cells. Recent reports indicate that expression of FasL in transplanted cells may cause graft rejection and, on the other hand, tumor cells may lose their tumorigenicity when they are engineered to express FasL. These effects could be related to recruitment of neutrophils by FasL with activation of their cytotoxic machinery. In this study we investigated the antitumor effect of allogenic fibroblasts engineered to express FasL. Fibroblasts engineered to express FasL (PA317/FasL) did not exert toxic effects on transformed liver cell line (BNL) or colon cancer cell line (CT26) in vitro, but they could abrogate their tumorigenicity in vivo. Histological examination of the site of implantation of BNL cells mixed with PA317/FasL revealed massive infiltration of polymorphonuclear neutrophils and mononuclear cells. A specific immune protective effect was observed in animals primed with a mixture of BNL or CT26 and PA317/FasL cells. Rechallenge with tumor cells 14 or 100 days after priming resulted in protection of 100 or 50% of animals, respectively. This protective effect was due to CD8+ cells since depletion of CD8+ led to tumor formation. In addition, treatment of pre-established BNL tumors with a subcutaneous injection of BNL and PA317/FasL cell mixture at a distant site caused significant inhibition of tumor growth. These data demonstrate that allogenic cells engineered with FasL are able to abolish tumor growth and induce specific protective immunity when they are mixed with neoplastic cells.  (+info)

Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. (7/8373)

Interleukin-12 (IL-12) is a potent antitumor cytokine, which induces and enhances the activity of natural killer (NK) cells, lymphokine activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). IL-12 also stimulates IFN-gamma production from both T cells and NK cells. In this study, we transfected methylcholanthrene-induced fibrosarcoma (MCA-D) with TNF gene and investigated the therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect is enhanced by systemic administration of recombinant IL-12 (rIL-12), in a murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL-12 showed slight or moderate inhibition of pre-established tumor. However, simultaneous application of the vaccine and rIL-12 resulted in complete eradication. The cytotoxicity of CTL against parental tumor cells was enhanced with the combination of the vaccine and rIL-12, and IFN-gamma production from spleen cells also increased synergistically. Our findings show that synergistic enhancement of CTL activity and IFN-gamma production could play an important role in the antitumor effect of combination therapy using TNF gene-transduced cancer vaccine and rIL-12.  (+info)

The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. (8/8373)

The murine antibody R24 and mouse-human Fv-IgG1(kappa) chimeric antibody chR24 are specific for the cell-surface tumor antigen disialoganglioside GD3. X-ray diffraction and surface plasmon resonance experiments have been employed to study the mechanism of "homophilic binding," in which molecules of R24 recognize and bind to other molecules of R24 though their heavy chain variable domains. R24 exhibits strong binding to liposomes containing disialoganglioside GD3; however, the kinetics are unusual in that saturation of binding is not observed. The binding of chR24 to GD3-bearing liposomes is significantly weaker, suggesting that cooperative interactions involving antibody constant regions contribute to R24 binding of membrane-bound GD3. The crystal structures of the Fabs from R24 and chR24 reveal the mechanism for homophilic binding and confirm that the homophilic and antigen-binding idiotopes are distinct. The homophilic binding idiotope is formed largely by an anti-parallel beta-sheet dimerization between the H2 complementarity determining region (CDR) loops of two Fabs, while the antigen-binding idiotope is a pocket formed by the three CDR loops on the heavy chain. The formation of homophilic dimers requires the presence of a canonical conformation for the H2 CDR in conjunction with participation of side chains. The relative positions of the homophilic and antigen-binding sites allows for a lattice of GD3-specific antibodies to be constructed, which is stabilized by the presence of the cell membrane. This model provides for the selective recognition by R24 of cells that overexpress GD3 on the cell surface.  (+info)

TY - JOUR. T1 - Decreased macrophage‐mediated cytotoxicity in mammary‐tumor‐bearing mice is related to alteration of nitric‐oxide production and/or release. AU - Sotomayor, Eduardo M.. AU - Dinapoli, Michael R.. AU - Calderón, Cesar. AU - Colsky, Arthur. AU - Fu, Yang‐Xin ‐X. AU - Lopez, Diana M.. PY - 1995/3/3. Y1 - 1995/3/3. N2 - Peritoneal‐exudate macrophages (PEM) from mammarytumor‐bearing mice have impaired cytotoxic activity against syngeneic and allogeneic tumor targets. The ability of PEM from normal and tumor‐bearing mice to bind tumor targets was found to be similar in the presence or the absence of surrogate receptors, which enhanced the binding but not the killing of tumor targets by PEM from tumor‐bearing mice, suggesting that other mechanisms are involved in their impaired cytolytic activity. Soluble and membrane‐bound TNF‐α, as well as H2O2, were found in higher amounts in PEM from tumor bearers upon stimulation with LPS, as compared with PEM from normal ...
Fogh, J; Fogh, J M.; and Orfeo, T, Tumor production in nude mice by cultured human tumor cell lines. Abstr. (1977). Subject Strain Bibliography 1977. 2541 ...
Looking for carcinomas, carcinomata? Find out information about carcinomas, carcinomata. see neoplasm neoplasm or tumor, tissue composed of cells that grow in an abnormal way. Normal tissue is growth-limited, i.e., cell reproduction is equal to... Explanation of carcinomas, carcinomata
Figure 4. Treg lineage instability removes intratumor immune suppression. A and B, experiment schematic: tumors were isolated and dissociated, and 10,000 live tumor cells were then embedded along with all tumor-infiltrating cells (∼3-5 times tumor cell counts) in collagen-fibrin gel together with or without CTLs as described in Materials and Methods. After 24, 48, and 72 hours, gels were lysed and viable cells were cultured in a colony-forming assay. No killing would appear with 100+ colonies, and killing would show very few colonies. A, graphs show number of viable tumor cells recovered at indicated time points for IgG (left) and DTA-1 (middle) for total tumors alone (blue line) or with activated OT-1 T cells (red line). Right, rate of B16 cell killing by OT-1 CTL (killing constant k, as calculated in Materiala and Methods), of IgG (dark gray) and DTA-1 (white) tumors is shown compared with primary tissue culture B16 cells alone (light gray). B, viable tumor cells recovered from cultures of ...
Rosenstein, M M.; Pelus, L M.; and Strausser, H R., Host-mediated immune suppression in tumor bearing mice. In vitro reversal by indomethacin or removal of adherent cells. Abstr. (1978). Subject Strain Bibliography 1978. 375 ...
Abstract. Concomitant tumor resistance (CR) is a phenomenon in which a tumor-bearing host is resistant to the growth of secondary tumor implants and metastasis. While former studies have indicated that T-cell dependent processes mediate CR in hosts bearing immunogenic small tumors, the most universal manifestation of CR induced by immunogenic and non-immunogenic large tumors had been associated with an antitumor serum factor that remained an enigma for many years. In a recent paper, we identified that elusive factor(s) as an equi-molar mixture of meta-tyrosine and ortho-tyrosine, two isomers of tyrosine that are not present in normal proteins and that proved to be responsible for 90% and 10%, respectively, of the total serum anti-tumor activity. In this work, we have extended our previous findings demonstrating that a periodic intravenous administration of meta-tyrosine induced a dramatic reduction of lung and hepatic metastases generated in mice bearing two different metastatic murine tumors ...
In the present study, a multivariable analysis of the CD8+ T-cell response in mice vaccinated with different recombinant vaccines encoding the melanoma antigen TRP-2 delineated three main situations. The simplest finding involved the activity of the powerful rAd-hTRP-2 vaccine in prophylaxis of tumor challenge. All of the mice mounted a vigorous immune response against the mouse Kb-restricted epitope, as indicated by the significant changes in the number and functions of TRP-2-specific T lymphocytes. The immune response was so strong that correlation with the number of metastases was not feasible because the majority of the mice did not present countable metastases after challenge with B16 (7 of 10 mice had no metastases). T lymphocytes stimulated with the TRP-2180-188 peptide in vitro also recognized the wild-type melanoma. Nevertheless, it must be noted that prophylactic vaccination with the xenogeneic form of the antigen, although valuable for several experimental mouse tumor antigens, would ...
Ethris proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA) platform includes a toolbox of technologies to generate mRNA molecules that are stable, result in production in the patients own body of therapeutic proteins, and which escape recognition by the bodys immune system. These mRNA technologies paired with Ethris proprietary delivery systems for organ- and cell- targeted delivery of mRNA has generated a pipeline of Transcript Therapies, which Ethris is developing to treat serious diseases ...
TY - JOUR. T1 - Comparison of L bleomycin prepared by two methods. T2 - Stability and pharmacokinetics in tumor bearing mice. AU - Krohn, K. A.. AU - Meyers, J.. AU - Denardo, Gerald L. PY - 1977. Y1 - 1977. UR - http://www.scopus.com/inward/record.url?scp=0017623084&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0017623084&partnerID=8YFLogxK. M3 - Article. C2 - 63131. AN - SCOPUS:0017623084. VL - 122. SP - 179. EP - 182. JO - Radiology. JF - Radiology. SN - 0033-8419. IS - 1. ER - ...
A competent and expanding vascular supply is a necessary component of the progressive growth of solid tumors because cells in solid tumors, like normal tissue, must receive oxygen and other nutrients to survive and grow (17) . The connection between oxygen supply and tumor growth was first made in the 1950s by radiobiologists who were aware of oxygen as a radiosensitizer and the fact that hypoxic cells in tumors are resistant to radiation therapy (18) . Histological analyses of human and rodent tumors performed by Thomlinson and Gray (18) were the first studies to suggest that regions of viable cells exist close to tumor blood vessels and that these walls or cords of viable tumor cells correspond in thickness to the distance that oxygen can diffuse (1-2 mm3). The tumor cord model implied that hypoxic cells exist in a state of oxygen and nutrient starvation at the limits of the diffusion range of oxygen, and it was hypothesized that tumor cells could proliferate and grow only if they were close ...
May be imported without a USDA permit.. In addition, monoclonal antibodies intended for in vivo human use do not require a permit.. However, (1) cell lines derived from livestock or avian species, (2) cell lines derived from any species which will be used for in vivo use, and (3) cell lines of any species which may have been exposed to exotic livestock or avian disease agents will require a USDA, VS import permit.. Procedures:. A USDA, VS import permit will NOT be required for cell lines other products of cell lines, including monoclonal antibodies if the shipment is accompanied by:. ...
A new study has shown that an experimental class of cancer drugs has wider potential than previously thought. Researchers have found a new type of BET inhibitor that, in mouse tests, can target solid tumors more effectively and safely than others.
Global Tumor Blood Testing Market Report 2020 has complete details about market of Tumor Blood Testing industry, Tumor Blood Testing analysis and current trends. Global Tumor Blood Testing Market Report 2020 Full Report: 2350 USD Multi License (Section): 4700 USD Section Price: As below Page: 115 Chart and Figure: 124 Publisher: BisReport Delivery Time: 24 hour At the beginning of 2020, COVID-19 disease began to spread around the world, millions of people worldwide were infected with COVID-19 disease, .
J:113221 Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P, Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun. 2006;6:10 ...
Patients think experimental cancer drugs will work for them, even though fewer than 5 percent ever benefit from early-phase studies.
PDT in tumor-bearing mice. (a) 4T1 cells were injected subcutaneously in two separate locations on the back of BALB/c mice. After tumors were established (marke
MTB has been designed to aid researchers in such areas as choosing experimental models, reviewing patterns of mutations in specific cancers, and identifying genes that are commonly mutated across a spectrum of cancers.
|p|SL-327 is a selective inhibitor of MEK1 and MEK2 with IC50 values of 0.18 and 0.22μM,  respectively.|br /|MEK1 and MEK2 (ERK) are a kinase enzyme which phosphorylate mitogen-activated protein kinase (MAPK). Extracellular signal-regulated kinase
Synthetic biology is driving a new era of medicine through the genetic programming of living cells1,2. This transformative approach allows for the creation of engineered systems that intelligently sense and respond to diverse environments, ultimately adding specificity and efficacy that extends beyond the capabilities of molecular-based therapeutics3-6. One particular area of focus has been the engineering of bacteria as therapeutic delivery systems to selectively release therapeutic payloads in vivo7-11. Here we engineered a non-pathogenic Escherichia coli strain to specifically lyse within the tumor microenvironment and release an encoded nanobody antagonist of CD47 (CD47nb)12, an anti-phagocytic receptor that is commonly overexpressed in several human cancer types13,14. We show that delivery of CD47nb by tumor-colonizing bacteria increases activation of tumor-infiltrating T cells, stimulates rapid tumor regression, prevents metastasis and leads to long-term survival in a syngeneic tumor model in mice
Cancer is one of the most dreaded diseases. It is estimated that more than eight million people die of cancer every year. Scientists believe that there are more than 100 types of cancer and each one of them has different levels of severity and mortality rates.. However, technology has brought great relief to cancer patients across the world. Doctors and scientists have been able to develop various cancer treatment options. Most of these treatment options although still at the experimental stage, have proved to cure different types of cancers.. Below are some of the exciting and experimental cancer treatment options:. ...
In this issue of Clinical Cancer Research, a new development in adoptive T-cell therapy experimental mouse tumor model is reported by Leisegang and colleagues (1).. In retrospect, the 1990s were considered a golden period for tumor immunology when many tumor antigens recognized by T cells were identified. The antigens reported by Boon and colleagues in both murine and human cancers (2, 3) were derived from genes that are overexpressed in cancer and fetal tissues (4). The second class of unmutated antigens recognized by tumor-reactive T cells is tissue-specific antigens that are also found in tumor cells (5). These unmutated tumor antigens were favored for cancer vaccines and cancer therapy because they are present in a high proportion of human cancers. However, the classical study by Prehn and Main (6) has cast a long shadow on the utility of the shared tumor antigen, as their in vivo analysis showed that tumor rejection antigens are by and large individually specific. In supporting this notion, ...
CD96 is a novel target for cancer immunotherapy shown to regulate NK cell effector function and metastasis. Here, we demonstrated that blocking CD96 suppressed primary tumor growth in a number of experimental mouse tumor models in a CD8+ T cell-dependent manner. DNAM-1/CD226, Batf3, IL12p35, and IFNγ were also critical, and CD96-deficient CD8+ T cells promoted greater tumor control than CD96-sufficient CD8+ T cells. The antitumor activity of anti-CD96 therapy was independent of Fc-mediated effector function and was more effective in dual combination with blockade of a number of immune checkpoints, including PD-1, PD-L1, TIGIT, and CTLA-4. We consistently observed coexpression of PD-1 with CD96 on CD8+ T lymphocytes in tumor-infiltrating leukocytes both in mouse and human cancers using mRNA analysis, flow cytometry, and multiplex IHF. The combination of anti-CD96 with anti-PD-1 increased the percentage of IFNγ-expressing CD8+ T lymphocytes. Addition of anti-CD96 to anti-PD-1 and anti-TIGIT ...
The time- and dose-dependent effects of recombinant human interleukin 1α (IL-1α) on the antitumor activity of mitomycin C (MMC) and porfiromycin (PORF) were studied in RIF-1 and Panc02 solid tumor model systems. IL-1α produced dose-dependent sensitization of clonogenic RIF-1 tumor cells to MMC in vivo. IL-1α chemosensitization was highly schedule dependent, and the most efficacious schedules produced dose-modifying factors of 3.6 and 5.1 for MMC and PORF, respectively. More than additive clonogenic cell kill after IL-1α-chemotherapy combinations reflected increased cellular sensitivity to MMC and PORF. The combinations also produced marked decreases in the yield of viable tumor cells, suggesting that the bioreductive drugs may have also potentiated the microvascular injury and ischemia produced by IL-1α. Dexamethasone inhibited and ketoconazole, an inhibitor of corticosterone biosynthesis, enhanced IL-1α-mediated chemosensitization in these models. IL-1α mediated chemosensitization to ...
|jats:p|The goal of this review is to pinpoint the specific features, including the weaknesses, of various tumor models, and to discuss the reasons why treatments that are efficient in murine tumor models often do not work in clinics. In a detailed comparison of transplanted and spontaneous tumor models, we focus on structure-function relationships in the tumor microenvironment. For instance, the architecture of the vascular tree, which depends on whether tumor cells have gone through epithelial-mesenchymal transition, is determinant for the extension of the spontaneous necrosis, and for the intratumoral localization of the immune infiltrate. Another key point is the model-dependent abundance of TGFβ in the tumor, which controls the variable susceptibility of different tumor models to treatments. Grounded in a historical perspective, this review provides a rationale for checking factors that will be key for the transition between preclinical murine models and clinical applications.|/jats:p|
Inoculation of mice from appropriate crosses with two strain A tumours and one dba (subline 2) tumour showed close linkage of such a gene with the locus for fused. With the A strain it was shown that the gene was identical with that for antigen II present in the erythrocytes. The gene is therefore labelled $H_{2}$. Of sixty-nine backcross mice tested, both serologically and by tumour inoculation, sixty-five gave concordant results, four discordant results. In general, it appears that serological tests are preferable to tumour inoculation in the identification of genotypes. On serological grounds it is suggested that the dba gene is an allele of the above and should be called $H_{2}{}^{d}$. It is possible that there is a long series of alleles at this locus. The indicated genotype of the strains used is as follows: $A,H_{2}H_{2}$; $dba,H_{2}{}^{d}H_{2}{}^{d}$; CBA, C57 and $P,h_{2}h_{2}$; $CA,Fu$ $h_{2}/fu$ $h_{2}$. Further tests may show differences in the $h_{2}$ allele in the last four ...
Consistent with previous observations, c-Met Inhibitors staining exposed substantial regions of hemorrhagic necrosis devoid of CD31 staining along with viable tumor cells and CD31 blood vessels in the tumor rim. Interestingly, CD31 immunostained sections of orthotopic MCA tumors showed a really selective vascular response to DMXAA with intact vasculature noticeable in the neighboring muscle tissue.. Evaluation of R1 values of muscle tissue had been consistent with this observation and showed no statistically important big difference amongst handle and treatment method groups. Ultimately, we determined if the differential vascular response to DMXAA among ectopic and orthotopic MCA tumors correlated with intratumoral levels of TNF, a principal cytokine concerned in antivascular activity of DMXAA. Differences in intratumoral VEGF ranges have been also analyzed. As proven in Fig. 5A, untreated handle MCA tumors established at ectopic and orthotopic tissue sites showed very reduced amounts of TNF, ...
iframe src=https://biblio.ugent.be/organization/GE17?embed=1&hide_pagination=1&hide_info=1&hide_options=1&hide_cluster=1 ...
iframe src=https://biblio.ugent.be/organization/GE17?embed=1&hide_pagination=1&hide_info=1&hide_options=1&hide_cluster=1 ...
CD45 (TIL) MicroBeads, mouse have been optimized for the isolation of tumor-infiltrating leukocytes from mouse tumors. - 대한민국
CD326 (EpCAM) MicroBeads have been developed for positive selection or depletion of epithelial cells or epithelial tumor cells comprising from single-cell preparation of tissues and organs expressing mouse CD326 (EpCAM) antigen. - 대한민국
Cancer cells possess a broad spectrum of migration and invasion mechanisms. These include both individual and collective cell-migration strategies. Cancer therapeutics that are designed to target adhesion receptors or proteases have not proven to be effective in slowing tumour progression in clinica …
The 1% are very different from you and me.. But they dont just eat, dress, and act differently…. They treat cancer differently too.. And heres the incredible part…. They DONT shell out hundreds of thousands for experimental cancer therapies.. They DONT visit overpriced hospitals, where theyre injected with radiation or poison.. And they DONT experience deadly side effects or die within 12 months from ineffective chemo.. Instead they apply a little-known cancer protocol - a safeguarded health secret in elite …. ...
Interleukin (IL)-21 is a recently discovered cytokine in early clinical development, which has shown anti-tumor activity in various animal models. In the present study, we examine the anti-tumor activ
China Dts-3 Three Phase Electrical Enrgy Meter Instruments, Find details about China Kwh Meter, Energy Meter from Dts-3 Three Phase Electrical Enrgy Meter Instruments - Yueqing Tainihan Electrical Technology Co., Ltd.
Background: The combination of two or more therapeutic drugs is an attractive approach to improve the treatment of experimental tumors. Leveraging nanocarrie
Looking for online definition of Neoplastic growth in the Medical Dictionary? Neoplastic growth explanation free. What is Neoplastic growth? Meaning of Neoplastic growth medical term. What does Neoplastic growth mean?
TY - JOUR. T1 - An. T2 - In vitro tumor swamp model of heterogeneous cellular and chemotherapeutic landscapes. AU - Lin, Ke Chih. AU - Sun, Yusha. AU - Torga, Gonzalo. AU - Sherpa, Pema. AU - Zhao, Yihua. AU - Qu, Junle. AU - Amend, Sarah R.. AU - Pienta, Kenneth J.. AU - Sturm, James C.. AU - Austin, Robert H.. N1 - Funding Information: This work was supported by NSF PHY-1659940 and the Princeton Catalysis Initiative. YS was supported by the SURE Program of the James Buchanan Brady Urological Institute at Johns Hopkins School of Medicine for a part of this research.. PY - 2020/7/21. Y1 - 2020/7/21. N2 - The heterogenous, highly metabolic stressed, poorly irrigated, solid tumor microenvironment-the tumor swamp-is widely recognized to play an important role in cancer progression as well as the development of therapeutic resistance. It is thus important to create realistic in vitro models within the therapeutic pipeline that can recapitulate the fundamental stress features of the tumor swamp. Here ...
Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the parameters governing tumor epitope immunogenicity remain unclear. Here, we assembled a global consortium wherein each participant predicted immunogenic epitopes from shared tumor sequencing data. 608 epitopes were subsequently assessed for T cell binding in patient-matched samples. By integrating peptide features associated with presentation and recognition, we developed a model of tumor epitope immunogenicity that filtered out 98% of non-immunogenic peptides with a precision above 0.70. Pipelines prioritizing model features had superior performance, and pipeline alterations leveraging them improved prediction performance. These findings were validated in an independent cohort of 310 epitopes prioritized from tumor sequencing data and assessed for T cell binding.
The identification of metarrestin began nearly a decade ago and involved a collaboration between Dr. Huangs lab at Northwestern and researchers at the University of Kansas and NIH.. The initial work was performed by investigators at NIHs National Center for Advancing Translation Sciences (NCATS), who developed a screen for systematically testing compounds-approximately 140,000 in total-in a prostate cancer cell line rife with PNC-containing cells. From that intensive process, they identified a compound that was highly effective at reducing PNC prevalence in the cells and that had other favorable features of a potential metastasis-blocking therapy.. Next, researchers from the University of Kansas and the NCATS Chemical Genomics Center, led by Juan Marugan, Ph.D., and a co-lead investigator on the study, formulated derivatives of the compound-approximately 150 different formulations to arrive at one with the greatest potency and other properties needed for a drug to work well in the human ...
Consistent with previous observations, c-Met Inhibitors staining exposed substantial regions of hemorrhagic necrosis devoid of CD31 staining along with viable tumor cells and CD31 blood vessels in the tumor rim. Interestingly, CD31 immunostained sections of orthotopic MCA tumors showed a really selective vascular response to DMXAA with intact vasculature noticeable in the neighboring muscle tissue.. Evaluation of R1 values of muscle tissue had been consistent with this observation and showed no statistically important big difference amongst handle and treatment method groups. Ultimately, we determined if the differential vascular response to DMXAA among ectopic and orthotopic MCA tumors correlated with intratumoral levels of TNF, a principal cytokine concerned in antivascular activity of DMXAA. Differences in intratumoral VEGF ranges have been also analyzed. As proven in Fig. 5A, untreated handle MCA tumors established at ectopic and orthotopic tissue sites showed very reduced amounts of TNF, ...
Health,...They target malignancies of the cervix prostate and breast among oth...TUESDAY April 15 (HealthDay News) -- A germ that commonly causes food...A new trial shows that a live Listeria vaccine called Lovaxin C is saf...Listeria is a common bacteria found on leafy vegetables and dairy prod...,Experimental,Cancer,Vaccines,Show,Promise,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Tetrabromoethane (TBE) is a halogenated hydrocarbon, chemical formula C2H2Br4. Although three bromine atoms may bind to one of the carbon atoms creating 1,1,1,2-tetrabromoethane this is not thermodynamically favorable, so in practice tetrabromoethane is equal to 1,1,2,2-tetrabromoethane, where each carbon atom binds two bromine atoms. It has an unusually high density for an organic compound, near 3 g/mL, due largely to the four bromine atoms ...
Despite early reports that brain surgery would not be an option for Senator Edward Kennedy, the lawmaker is recovering after a successful operation, which was carried out at Duke University Medical Center today. The delicate procedure was performed by Allan Friedman, a highly-respected neurosurgeon, and will be followed by focused radiation and chemotherapy. Since none \[…\]
A series of amidoximes was prepared and evaluated for possible antitumor activity against L1210 leukemia. Three of the most active compounds in the L1210 system, formamidoxime, acetamidoxime, and 2-aminoacetamidoxime hydrochloride, were also active against P388 leukemia. Acetamidoxime was marginally active against Lewis lung carcinoma. The active amidoximes showed best activity against L1210 leukemia when given two times daily, 5 hours apart, for 8 days. Most of the amidoximes produced excessive central nervous system stimulation.
NSCLC tumors are appropriate targets for active immunotherapy, because they are non-immunogenic, which indicates that NSCLC does not stimulate a spontan
|p||strong|Technical Advantage: |/strong| This formulation in not available from other suppliers|br /| McCoys 5A medium was originally formulated to meet the culture requirements of Novikoff Hepatoma cells, and has been found to support the indefinite proliferation of Walker256 carcinoma cells along with a wide range of human and rat normal and transformed cells.  Originally modified by Iwakata and Grace, this version of McCoys 5A includes increased levels of inositol and glucose, and contains L-glutamine and 25 mM HEPES.|br /| -  Complete Certificate of Analysis available for each production lot, along with full formulation information|br /| -  Produced under the highest industry standards to ensure superior results|/p|
In the last chapter, characteristics and mechanisms of the early stages of neoplastic develop- ment-initiation and promotion-were presented as being the result of cellular and molecular changes induced by specific ...
Circulating Tumor Cells (CTCs) have been extensively explored as circulating biomarkers in various cancers. Due to their rarity, heterogeneity and stem cell-like properties, detecting and pro
Researchers reveal how an antidepressant and an experimental cancer drug stopped brain cell death in mouse models of dementia and prion disease.
Here we describe a method to separate and enrich components of the tumor immune and non-immune microenvironment in established...
The number of patients with neoplastic lesions, adenomas, adenomas 1 cm or more in diameter and adenocarcinoma was similar in both groups ...
Identify the cell parts using the clues provided. 1. THORCSPALLO 2. LEEREACNMBML 3. OUVLEAC 4. LCOSNUULE 5. BDOGLYIOG 6. ORMCIATNH Im needed for food. Im the outside of an animal cell. You name it - I can store it! I make ribosomes. I work with the ER. Im full of genetic information.
"Advances in Experimental Medicine and Biology. 618: 181-93. doi:10.1007/978-0-387-75434-5_14. ISBN 978-0-387-75433-8. . PMID ... Wick MR, Hornick JL (2011). "Immunohistology of Soft Tissue and Osseous Neoplasms". Diagnostic Immunohistochemistry. Elsevier. ... "The Journal of Experimental Biology. 207 (Pt 20): 3441-6. doi:10.1242/jeb.01172. PMID 15339940.. ...
"A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 (5): 696-705. doi:10.1084/ ... "The Journal of Experimental Medicine. 22 (5): 646-673. doi:10.1084/jem.22.5.646. PMC 2125363 . PMID 19867946.. ... "The Journal of Experimental Medicine. 201 (3): 320. doi:10.1084/jem.2013fta. PMC 2213042 . PMID 15756727.. ... Journal of Experimental Medicine. 13 (4): 397-411. doi:10.1084/jem.13.4.397. PMC 2124874 . PMID 19867421.. ...
G1 and G2 neuroendocrine neoplasms are called neuroendocrine tumors (NETs) - formerly called carcinoid tumours. G3 neoplasms ... An analysis of 11842 reported cases". Journal of Experimental & Clinical Cancer Research. 22 (4): 517-30. PMID 15053292. Soga, ... Although there are many kinds of NETs, they are treated as a group of tissue because the cells of these neoplasms share common ... Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. They most ...
Endometrioid cystadenoma (8380) Appendix: The term mucinous cystadenoma is an obsolete term for appendiceal mucinous neoplasm ... Clinical and Experimental Hepatology. 5 (1): 22-29. doi:10.5114/ceh.2019.83153. PMC 6431089. PMID 30915403. Michael Feely, Raul ... "Appendix - Other tumors - Mucinous neoplasms (LAMN and HAMN)". Topic Completed: 1 October 2017. Revised: 11 December 2019 ...
Sometimes experimental autoimmune encephalomyelitis has been triggered in humans by accident or medical mistake. The damage in ... They look like intracranial neoplasms, and sometimes they get biopsied as suspected tumors. Proton MR spectroscopy can help in ...
Horn L, Lovly CM (2018). "Chapter 74: Neoplasms of the lung". In Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo ... International Journal of Clinical and Experimental Pathology. 1 (1): 19-31. PMC 2480532. PMID 18784820. Connolly JL, Goldsmith ... Tan D, Zander DS (January 2008). "Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update ...
Watrin E, Peters JM (August 2006). "Cohesin and DNA damage repair". Experimental Cell Research. 312 (14): 2687-93. doi:10.1016/ ... October 2013). "Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms". Nature Genetics. 45 ( ... October 2015). "Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms". The ... Experimental Cell Research. 316 (9): 1445-53. doi:10.1016/j.yexcr.2009.12.018. PMID 20043905. Wendt KS, Yoshida K, Itoh T, ...
Rous, Peyton (1910). "A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 (5): ... Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk ... STEWART, SE; EDDY, BE; BORGESE, N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Experimental Biology and Medicine. 83 (2): 414-21. doi:10.3181/00379727-83-20376. PMID 13064287. S2CID 34223353. ...
Rous, Peyton (1910). "A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 (5): ... Journal of Experimental Medicine. 13 (4): 397-411. doi:10.1084/jem.13.4.397. PMC 2124874. PMID 19867421. Rous as oldest ... for the discovery of carcinogenic viruses and for Charles Huggins for the introduction of hormones for treatment of neoplasms ...
Rous, Peyton (1910-09-01). "A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 ... January 12-13 - Birth of public radio broadcasting: Lee De Forest conducts an experimental broadcast of part of a live ...
In the neuroectodermal component of the tumors, neuroblastic neoplasm was the most common presentation (4/6) and the other two ... Experimental Neurology. 30 (2): 290-309. doi:10.1097/00005072-197104000-00010. ISSN 0022-3069. PMID 4947980. Holimon, J. L.; ... The first records of ectomesenchymoma are from 1971 in an investigation into neoplasms of mixed mesenchymal and neuroepithelial ... Shuangshoti, Samruay; Netsky, Martin G. (1971-04-01). "Neoplasms of Mixed Mesenchymal and Neuroepithelial OriginRelation to " ...
Journal of Clinical & Experimental Pathology", 2013-07-26. *↑ a b c d e JW. Vardiman, J. Thiele, DA. Arber, RD. Brunning i inni ... Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci.. „Proc Natl Acad Sci U ... The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and ...
Advances in Experimental Medicine and Biology. 577. pp. 73-84. doi:10.1007/0-387-32957-9_5. ISBN 978-0-387-29233-5. PMID ... Stewart SE, Eddy BE, Borgese N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Proceedings of the Society for Experimental Biology and Medicine. 83 (2): 414-21. doi:10.3181/00379727-83-20376. PMID 13064287 ...
It has been shown to cause retardation of some malignant neoplasms when administered to tumors in animals. 8-Azaguanine was the ... first purine analogue discovered to inhibit experimental tumors in mice. * Sources: "Azaguanine - Compound Summary (Descriptors ...
STEWART, SE; EDDY, BE; BORGESE, N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Experimental Biology and Medicine. 83 (2): 414-21. doi:10.3181/00379727-83-20376. PMID 13064287. S2CID 34223353. ...
Table 3 from: Weiss, Lawrence M.; Gelb, Arnold B.; Jeffrey Medeiros, L. (1995). "Adult Renal Epithelial Neoplasms". American ... International Journal of Clinical and Experimental Pathology. 2 (5): 489-93. PMC 2655150. PMID 19294008. Batai K, Harb-De la ... of all kidney neoplasms. Based on its morphological features, PRCC can be classified into two main subtypes, which are type 1 ( ... International Journal of Clinical and Experimental Pathology. 8 (7): 8311-35. PMC 4555730. PMID 26339402. Zarrabi K, Fang C, Wu ...
... myeloproliferative neoplasm cells". Experimental Hematology. 40 (8): 634-45.e10. doi:10.1016/j.exphem.2012.04.007. PMID ...
... inflammatory bowel disease and experimental autoimmune encephalomyelitis In experimental colitis-induced colon carcinoma, ... a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms". American Journal of Clinical ... This increase results in higher inflammatory responses and tissue damage in experimental models of contact dermatitis, ... Advances in Experimental Medicine and Biology. 313: 69-78. doi:10.1007/978-1-4899-2444-5_7. ISBN 978-1-4899-2446-9. PMID ...
In experimental evaluation of specific DNA repair deficiencies in cancers, many specific DNA repair deficiencies were also ... ICD-10 classifies neoplasms into four main groups: benign neoplasms, in situ neoplasms, malignant neoplasms, and neoplasms of ... The term 'neoplasm' is a synonym of "tumor". 'Neoplasia' denotes the process of the formation of neoplasms/tumors, the process ... "II Neoplasms". World Health Organization. Retrieved 19 June 2014.. *^ a b Abrams, Gerald. "Neoplasia I". Retrieved 23 January ...
"A transmissible avian neoplasm. (Sarcoma of the common fowl) by Peyton Rous, M.D., Experimental Medicine for Sept. 1, 1910, vol ...
Takata K, Miyata-Takata T, Sato Y, Yoshino T (2014). "Pathology of follicular lymphoma". Journal of Clinical and Experimental ... "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-90. doi:10.1182 ... Other mostly experimental treatments currently under study in patients with multiple treatment failures include: 1) ...
"International Journal of Clinical and Experimental Pathology. 5 (5): 382-96. PMC 3396065. PMID 22808291.. Review. ... Thus, a clone with a mutation in a tumor suppressor gene or oncogene will expand only in a neoplasm if that mutation gives the ... Some of the small polyps in the field defect shown in the photo of the opened colon segment may be relatively benign neoplasms ... In experimental evaluation of specific DNA repair deficiencies in cancers, many specific DNA repair deficiencies were also ...
It is used mainly as an experimental mutagen, but its deoxyriboside derivative (5-bromo-2-deoxy-uridine) is used to treat ... neoplasms. 5-BrU exists in three tautomeric forms that have different base pairing properties. The keto form (shown in the ...
... (LY-2784544) is an experimental drug developed by Eli Lilly for treatment of cancer. It is a small molecule JAK2 ( ... A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or ... "A Study of LY2784544 in Participants With Myeloproliferative Neoplasms - Full Text View - ClinicalTrials.gov".. ...
"The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375-90. doi:10.1182 ... International Journal of Clinical and Experimental Pathology. 10 (9): 9541-9550. PMC 6965900. PMID 31966830. Ponzoni M, Campo E ...
Kent, S. P.; Pickering, J. E. (1958). "Neoplasms in monkeys (Macaca mulatta): spontaneous and irradiation induced". Cancer. 11 ... The Journal of Experimental Medicine. 104 (3): 435-442. doi:10.1084/jem.104.3.435. PMC 2136567. PMID 13357695. Phillips M. ... Experimental Neurology. 17 (1): 12-57. doi:10.1097/00005072-195801000-00003. Pickering, J. E.; Brown, D. (1959). "Nuclear ... Pulmonary Ventilation and Oxygen Consumption Changes in Rhesus Monkeys Associated with Whole-Body Gamma-Irradiation Neoplasms ...
Also, "plexiform neuroma" (a neoplasm consisting of twisted bundles of nerves) is sometimes referred to as "Verneuil's neuroma ... ". He was primary author of Etudes experimentales et cliniques sur la tuberculose (Experimental and clinical studies on ...
Comparison of Neoplasms in Six Sources of Rats *^ Diamond JM (January 2006). Collapse: How Societies Choose to Fail or Succeed ... "The Journal of Experimental Medicine. 124 (2): 227-40. doi:10.1084/jem.124.2.227. PMC 2180468. PMID 4380670.. ... "International Journal of Experimental Pathology. 88 (6): 437-43. doi:10.1111/j.1365-2613.2007.00554.x. PMC 2517339. PMID ... Krinke GJ, Bullock GR, Krinke G (June 15, 2000). "History, Strains and Models". The Laboratory Rat (Handbook of Experimental ...
... each experimental units is measured at more than one time point; experimental units fall into a one or two class design Pattern ... and neoplasms. Significance analysis of microarrays (SAM) is a statistical technique, established in 2001 by Virginia Tusher, ... ri is equal to the expression levels (x) for gene i under y experimental conditions. F a l s e d i s c o v e r y r a t e ( F D ... A further approach is contextual meta-analysis, i.e. finding out how a gene cluster responds to a variety of experimental ...
Experimental treatments include targeted therapy, gamma knife radiosurgery,[45] boron neutron capture therapy and gene therapy. ... Neoplasms will often show as differently colored masses (also referred to as processes) in CT or MRI results. ... A variety of experimental therapies are available through clinical trials.. Survival rates in primary brain tumors depend on ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ...
Experimental approaches in sensory substitution are beginning to provide access to arbitrary live views from a camera. ... Malignant neoplasms of the brain and nervous system (1.5%). *Retinal detachment (1.4%) ... Two experimental treatments for retinal problems include a cybernetic replacement and transplant of fetal retinal cells.[71] ...
... neoplasm - nephrotoxic - neuralgia - neurological complications of AIDS - neuropathy - neutralization - neutralizing antibody ... experimental drug - expression system ...
Neoplasms 60% increase in death rate 60% increased death rate from neoplasms. In 1999-2003, neoplasms accounted for 17% of all ... "3302.0.55.003 - Experimental Life Tables for Aboriginal and Torres Strait Islander Australians, 2005-2007". Australian Bureau ...
... though these are currently experimental. ... cystic neoplasms: Serous microcystic adenoma. *Intraductal ...
ISBN 0-7020-2606-9. Huete-Garin, A.; S.S. Sagel (2005). "Chapter 6: "Mediastinum", Thymic Neoplasm". In J.K.T. Lee; S.S. Sagel ... Clinical and Experimental Immunology. 145 (3): 407-412. doi:10.1111/j.1365-2249.2006.03139.x. PMC 1809694 . PMID 16907907. ...
"Journal of Experimental & Clinical Cancer Research. 34 (1): 92. doi:10.1186/s13046-015-0207-9. PMC 4559261. PMID 26338018.. ... Large cell lung carcinoma (LCLC) is a heterogeneous group of undifferentiated malignant neoplasms originating from transformed ... in that the tumor cells lack light microscopic characteristics that would classify the neoplasm as a small-cell carcinoma, ...
In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a ... Experimental Hematology. 38 (11): 1058-65. doi:10.1016/j.exphem.2010.07.005. PMID 20655352.. ... These mutations are not specific to myelofibrosis, and are linked to other myeloproliferative neoplasms, specifically ... Barosi, Giovanni (2011). "Conventional and Investigational Therapy for Primary Myelofibrosis". Myeloproliferative Neoplasms. pp ...
"The Journal of Experimental Medicine. 37 (4): 525-42. PMC 2128372 . PMID 19868743. doi:10.1084/jem.37.4.525.. ... Secondary neoplasm[edit]. Development of secondary neoplasia after successful chemotherapy or radiotherapy treatment can occur ... "The Tohoku Journal of Experimental Medicine. 219 (3): 177-86. PMC 2927105 . PMID 19851045. doi:10.1620/tjem.219.177.. ... Main article: Experimental cancer treatments. Targeted therapies[edit]. Specially targeted delivery vehicles aim to increase ...
McGregor NR (November 2007). "Pueraria lobata (Kudzu root) hangover remedies and acetaldehyde-associated neoplasm risk". ... Clinical and Experimental Research. 27 (8 Suppl): 37S-41S. doi:10.1097/01.ALC.0000078828.49740.48. PMID 12960505.. ... Clinical and Experimental Research. 31 (3): 390-4. doi:10.1111/j.1530-0277.2006.00319.x. PMID 17295722.. ... Clinical and Experimental Research. 30 (Suppl. 6): 53A. doi:10.1111/j.1530-0277.2006.00150.x.. ...
Carcinogenesis and Neoplasm) and reference[24]). Furthermore, the ability of HRR to accurately and efficiently repair double- ... Experimental Cell Research. 283 (1): 1-16. doi:10.1016/S0014-4827(02)00027-7. PMID 12565815.. ...
"An Experimental Survey of Metal Artefact Reduction in Computed Tomography" (PDF). Journal of X-Ray Science and Technology. 21 ... superior information as compared to CT scans when seeking information about headache to confirm a diagnosis of neoplasm, ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment ...
Experimental treatments include targeted therapy, gamma knife radiosurgery,[49] boron neutron capture therapy and gene therapy. ... The skull bone structure can also be subject to a neoplasm that by its very nature reduces the volume of the intracranial ... A variety of experimental therapies are available through clinical trials.. Survival rates in primary brain tumors depend on ... "CNS and Miscellaneous Intracranial and Intraspinal Neoplasms" (PDF). SEER Pediatric Monograph. National Cancer Institute. pp. ...
"The Journal of Pharmacology and Experimental Therapeutics. 174 (2): 206-10. PMID 4393764.. ... Bernatsky S, Clarke AE, Suissa S (February 2008). "Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis ... Myeloproliferative neoplasms, including acute leukemia, non-Hodgkin lymphoma and multiple myeloma, occurred in 5 of 119 ... Clinical and experimental experiences with metallic cyclical and non-cyclical Phosphamidestern the N-losl in the chemotherapy ...
Experimental Cell Research. 294 (2): 345-55. doi:10.1016/j.yexcr.2003.11.022. PMID 15023525.. ... Neoplasm: Tumor suppressor genes/proteins and Oncogenes/Proto-oncogenes. Ligand. Growth factors. ... Journal of Experimental & Clinical Cancer Research. 25 (1): 5-14. PMID 16761612.. ...
Coley, William (1949). Neoplasms of Bone. New York: Medical Book Department of Harper & Brothers. pp. 565-570.. ... Since its changed status under the FDA, it has only been able to be prescribed through experimental clinical trials, which have ...
M. A. S. Moore ja J. J. T. Owen, EXPERIMENTAL STUDIES ON THE DEVELOPMENT OF THE THYMUS, J Exp Med. 1967 1. oktoober; 126(4): ... Tseng-Tong Kuo, Classification of thymic epithelial neoplasms: a controversial issue coming to an end?, J.Cell.Mol.Med. 5. ... Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK, Pathogenesis of experimental Ebola Zaire virus infection ... Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK, Pathogenesis of experimental Ebola Zaire virus infection ...
"Journal of Experimental & Clinical Cancer Research. 30 (1): 11. doi:10.1186/1756-9966-30-11. PMC 3032743. PMID 21247505.. This ... Srikumar Chakravarthi; Baba Krishnan; Malathy Madhavan (1999). "Apoptosis and expression of p53 in colorectal neoplasms". ... As summarized in the articles Carcinogenesis and Neoplasm, for sporadic cancers in general, a deficiency in DNA repair is ...
Journal of Experimental Biology. 204 (Pt 24): 4345-4351. ISSN 0022-0949. PMID 11815658. Retrieved 2009-09-18. With the species ...
"The Journal of Experimental Medicine. 195 (11): 1379-86. doi:10.1084/jem.20020170. PMC 2193540. PMID 12045236.. ... "GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms". Annals of Laboratory Medicine. 38 (4): 296-305. doi: ... Shimizu R, Yamamoto M (August 2016). "GATA-related hematologic disorders". Experimental Hematology. 44 (8): 696-705. doi: ... The Tohoku Journal of Experimental Medicine. 242 (2): 83-91. doi:10.1620/tjem.242.83. PMID 28566565.. ...
"Experimental Biology and Medicine. 60 (2): 259-262. doi:10.3181/00379727-60-15154P. Retrieved 13 December 2014.. ... Folate deficiency hinders DNA synthesis and cell division, affecting hematopoietic cells and neoplasms the most because of ...
Proksch, E; Brandner, JM; Jensen, JM (2008). "The skin: an indispensable barrier". Experimental Dermatology. 17 (12): 1063-72. ... Diseases of the skin include skin infections and skin neoplasms (including skin cancer). ...
An experimental procedure to treat type 1 diabetes is the transplantation of pancreatic islet cells from a donor into the ... "Solid pseudopapillary neoplasm of the pancreas: a single institution experience of 14 cases". HPB. 8 (2): 148-50. doi:10.1080/ ...
Tumors: Skin neoplasm, skin appendages / Adnexal and skin appendage (C44.L40-L68/D23.L15-49, 173/216) ... Advances in Experimental Medicine and Biology. 624: 89-103. doi:10.1007/978-0-387-77574-6_8. ISBN 978-0-387-77573-9. . PMID ... Tumors: Skin neoplasm, nevi and melanomas (C43/D22, 172/216, ICD-O 8720-8799) ... Clinical and Experimental Dermatology. 35 (1): 7-11. doi:10.1111/j.1365-2230.2009.03465.x. PMID 19778305.. ...
"Clinical and experimental immunology. 156 (1): 1-11. doi:10.1111/j.1365-2249.2008.03857.x. PMC 2673735 . PMID 19210521.. ... creates immunodeficiencies which allow opportunistic infections or neoplasms to proliferate. Bacterial processes leading to ... Li, J; Zhang, YY; Wang, NN; Bhandari, R; Liu, QQ (April 2016). "Riga-Fede disease in a child". Clinical and experimental ...
"Islet Cell Tumors of the Pancreas / Endocrine Neoplasms of the Pancreas". The Sol Goldman Pancreas Cancer Research Center. ... In 1907-08, after some more unsuccessful operations by other surgeons, experimental procedures were tried on corpses by French ... Pancreatic mucinous cystic neoplasms are a broad group of pancreas tumors that have varying malignant potential. They are being ... The third type, pancreatic mucinous cystic neoplasms (MCNs) mainly occur in women, and may remain benign or progress to cancer. ...
The Tohoku Journal of Experimental Medicine. 196 (2): 53-64. doi:10.1620/tjem.196.53. PMID 12498316.. ... neoplasms of the central nervous system, emotional and behavior disorders, and intellectual disability.[23] ...
Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology. 524: 181-7. doi:10.1007/0-306- ... with its levels either on the cell surface or in the serum increased in some neoplasms and decreased in others.[13] ... Advances in Experimental Medicine and Biology. 524: 3-17. doi:10.1007/0-306-47920-6_1. ISBN 0-306-47717-3. PMID 12675218.. ... Advances in Experimental Medicine and Biology. 575: 27-32. doi:10.1007/0-387-32824-6_3. ISBN 978-0-387-29058-4. PMID 16700505. ...
... Summary. Summary: Experimentally induced mammary neoplasms in animals to provide a model for ... You are here: Research Topics , diseases , animal diseases , animal mammary neoplasms , experimental mammary neoplasms ... neoplasm metastasis*lung neoplasms*inbred c3h mice*anticarcinogenic agents*pathologic neovascularization*inbred f344 rats* ... neoplasm transplantation*breast neoplasms*methylnitrosourea*carcinogens*adenocarcinoma*nude mice*transgenic mice*antineoplastic ...
Experimental from related diseases, pathways, genes and PTMs with the Novus Bioinformatics Tool. ... Liver Neoplasms, Experimental: Disease Bioinformatics. Research of Liver Neoplasms, Experimental has been linked to Liver ... Carcinoma, Neoplasms, Carcinoma, Malignant Neoplasms, Hepatocarcinogenesis. The study of Liver Neoplasms, Experimental has been ... Explore more on Liver Neoplasms, Experimental below! For more information on how to use Laverne, please read the How to Guide. ...
Experimental" by people in Harvard Catalyst Profiles by year, and whether "Mammary Neoplasms, Experimental" was a major or ... "Mammary Neoplasms, Experimental" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH ( ... Below are the most recent publications written about "Mammary Neoplasms, Experimental" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Mammary Neoplasms, Experimental". ...
Also Known As: Liver Neoplasms, Experimental; Experimental Hepatoma; Experimental Hepatomas; Hepatomas, Experimental; Neoplasms ... Key Therapies for Experimental Liver Neoplasms. Efficacy Chart ,, * Photochemotherapy (Photodynamic Therapy) : 1 study in 3 ... Experimental Liver Neoplasms Summary Description: Experimentally induced tumors of the LIVER.. ... Key Drugs and Agents for Experimental Liver Neoplasms. Efficacy Chart ,, Drugs and Important Biological Agents (IBA) related to ...
The Effect of 5-Amino-7-Hydroxy-1H-v-Triazolo (d) Pyrimidine (Guanazolo) on a Variety of Neoplasms in Experimental Animals. ... The Effect of 5-Amino-7-Hydroxy-1H-v-Triazolo (d) Pyrimidine (Guanazolo) on a Variety of Neoplasms in Experimental Animals ... The Effect of 5-Amino-7-Hydroxy-1H-v-Triazolo (d) Pyrimidine (Guanazolo) on a Variety of Neoplasms in Experimental Animals ... The Effect of 5-Amino-7-Hydroxy-1H-v-Triazolo (d) Pyrimidine (Guanazolo) on a Variety of Neoplasms in Experimental Animals ...
Experimental information including symptoms, causes, diseases, symptoms, treatments, and other medical and health issues. ... Introduction: Neoplasms, Experimental. Description of Neoplasms, Experimental. Neoplasms, Experimental: Experimentally induced ... Hierarchical classifications of Neoplasms, Experimental. The following list attempts to classify Neoplasms, Experimental into ... These medical condition or symptom topics may be relevant to medical information for Neoplasms, Experimental: *Neoplasms (16 ...
JEMJournal of Experimental Medicine. *JGPJournal of General Physiology. *LSALife Science Alliance ... Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. W S Pear, W ... W S Pear, J C Aster, M L Scott, R P Hasserjian, B Soffer, J Sklar, D Baltimore; Exclusive development of T cell neoplasms in ...
6. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding ... Treatment of all T and NK neoplasms should be within the context of a clinical trial if possible as standard therapy gives ... Mature B-CELL neoplasms in Chernobyl clean-up workers of 1986-1987: summary of cytomorphological and immunocytochemical study ... Natural killer (NK) cells are closely related to T cells and neoplasms derived from these are therefore considered within the ...
Neoplasms - genetics Neoplasms, Experimental Disease Models, Animal Models, Genetic Mice, Transgenic Laboratory Manuals ISBN. ... Drug Resistance, Neoplasm Genes, Tumor Suppressor Neoplasms, Experimental - therapy Signal Transduction ISBN. 1573315435 (cloth ... Neoplasms, Experimental Disease Models, Animal ISBN. 0896038874 Language. English Material Type. Book Agency. BC Cancer Agency ... Neoplasms, Experimental Laboratory Animal Science Research Animals, Laboratory ISSN. 1532-0820 Language. English Material Type ...
Modulators of experimental carcinogenesis : proceedings of a symposium held in Moscow, 28-30 June 1982 / organized by the IARC ... Tobacco and tobacco smoke : studies in experimental carcinogenesis / Ernest L. Wynder and Dietrich Hoffmann.. by Wynder, Ernest ...
... the role of integrin receptors as well as of some of their ligands of the extracellular matrix in cases of parotid neoplasms is ... INTEGRIN RECEPTORS AND EXTRACELLULAR MATRIX COMPONENTS IN PAROTID NEOPLASMS. Charalabopoulos Konstantinos1, Mittari Evanthia1, ... the role of integrin receptors as well as of some of their ligands of the extracellular matrix in cases of parotid neoplasms is ...
Neoplasms Language: Chinese Journal: Journal of Experimental Hematology Year: 2019 Type: Article ... Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms / 中国 ... between the polymorphism of TET2 gene SNP rs3733609 and JAK2V617F allele burden in patients with myeloproliferative neoplasms ( ...
Although uncommon, a neoplasm-like mass lesion on MRI can actually be a focal cerebritis, which more rarely can be idiopathic. ... We are reporting a challenging case of a focal brain lesion mimicking neoplasm that presented with a seizure caused by ... Idiopathic Focal Cerebritis Mimicking a Neoplasm.J Neurol Exp Neurosci 5(2): 106-109. ...
Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Leucovorin. Folic Acid. Oxaliplatin. Fluorouracil ... Experimental: Arm A (zolbetuximab plus mFOLFOX6) Participants will receive a loading dose of zolbetuximab at Cycle 1 Day 1 ... a placebo with mFOLFOX6 A placebo is a treatment that looks like the experimental medicine, but contains no medicine. ... This study is testing an experimental medicine called zolbetuximab (IMAB362). Zolbetuximab attaches itself to Claudin 18.2 on ...
Neoplasms, Connective and Soft Tissue. Neoplasms by Histologic Type. Neoplasms. Herpesviridae Infections. DNA Virus Infections ... Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposis Sarcoma in AIDS Patients. This study has been ...
Experimental: Venetoclax *Venetoclax is administered on a daily basis orally.. *The investigators will use a modified 3+3 with ... Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The safety and ... Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ... Histologically confirmed diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) per 2016 WHO criteria ...
Data from experimental studies have revealed two categories of metastatic dormancy: cellular dormancy, with solitary cancer ... Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches Future Oncol. 2009 Sep;5(7):1083- ... Neoplasms / therapy ...
Neoplasm Transplantation * Ovarian Neoplasms / pathology* * Salivary Gland Neoplasms / pathology* * Sarcoma, Experimental / ...
Neoplasms. REFERENCES. Chapter 34. The Experimental Use of Syrian Hamsters. Introduction. Cancer Research ... common experimental methods, and use of the species as a research model. With many expert contributors, this will be an ...
Advances in Experimental Medicine and Biology. Series Volume. 853. Copyright. 2015. Publisher. Springer International ... "This is an excellent textbook regarding the molecular and cell biology with respect to brain and spine neoplasms. This is a ... Stem Cell Biology in Neoplasms of the Central Nervous System. Editors. * Moneeb Ehtesham ... Stem Cell Biology in Neoplasms of the Central Nervous System. Editors: Ehtesham, Moneeb (Ed.) ...
Experimental: EUS-guided RFA EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed ... Pancreatic Neoplasms. Neoplasms. Digestive System Neoplasms. Neoplasms by Site. Endocrine Gland Neoplasms. Digestive System ... EUS-guided RFA for Pancreatic Neoplasms. The safety and scientific validity of this study is the responsibility of the study ... Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. Recently, EUS- ...
Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms / 中国实验血液学杂志 ... negative myeloproliferative neoplasms (MPN), so as to provide evidence for diagno-sis and treatment of the disease.,/p,,p,,b, ... Journal of Experimental Hematology Year: 2018 Type: Article ...
In this study we present 7 patients with Intraductal Papillary Mucinous Neoplasm (IPMN) studied both with 18FDG-PET and ... while absence of FDG uptake in the neoplasm area was recorded in the remaining 5 cases. Mean follow-up was 27 months (range 21- ... some clinical and radiological features may predict malignancy presence in intraductal papillary mucinous pancreas neoplasms, ... Journal of Experimental & Clinical Cancer Research volume 27, Article number: 10 (2008) Cite this article ...
Journal of Experimental and Clinical Surgery ISSN 2070-478X (Print). ISSN 2409-143X (Online) ... Home , Archives , Vol 8, No 3 (2015) , Reserves to Reduce Mortality from Malignant Neoplasms in a Specialized Oncology Service ...
in subjects: Experimental Neoplasms Your Search Terms: Other Search Options Toggle Dropdown *Guided Search ... In the experimental model, cells from the human small cell lung carcinoma cell line NCI-H69 cells were inoculated into the ... All experimental animals receiving the gliosarcoma cells and not treated died within four weeks. Treated animals surviving 113 ... Description: The purpose of this study was to evaluate the therapeutic efficacy of Re-188-RC-160 in experimental models of ...
Keyword: Experimental Neoplasms * Keyword: Mice * Keyword: Radiotherapy * STI Subject Categories: 55 Biology And Medicine, ...
Experimental: 1 Intervention: Biological: CVX-045. Publications * Not Provided * Includes publications given by the data ... Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, MalignancySafety And PK Study Of CVX-060 In Patients With Advanced Solid ... Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, MalignancyA Safety And Pharmacokinetic Study With CVX-045 In Patients With ...
Experimental: Palbociclib Description Patients who fulfill eligibility criteria will be entered into the trial to receive ...
Purchase Steroidal Activity in Experimental Animals and Man - 1st Edition. Print Book & E-Book. ISBN 9781483230351, ... V. Neoplasms of the Female Genital Tract VI. Renal Tumors in the Hamster VII. Lymphoid Tumors in Mice VIII. Miscellaneous ... Steroidal Activity in Experimental Animals and Man 1st Edition. 0.0 star rating Write a review ... Experimental Prostatic Cancer III. The Cooperative Study Program IV. The Nature of Relapse V. Summary and Conclusions ...
... developed by me for the Experimental Pathology Curriculum of the Department of Pathology at the Medical College of Virginia. In ... Expression of Differentiated Function in Neoplasms Robert G. McKinnell. Pages 435-460 ... outlines and selected histopathology laboratory components of an advanced course entitled The Pathobiology of Experimental ...
  • Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. (labome.org)
  • Mammary Neoplasms, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (harvard.edu)
  • This graph shows the total number of publications written about "Mammary Neoplasms, Experimental" by people in Harvard Catalyst Profiles by year, and whether "Mammary Neoplasms, Experimental" was a major or minor topic of these publication. (harvard.edu)
  • Below are the most recent publications written about "Mammary Neoplasms, Experimental" by people in Profiles. (harvard.edu)
  • The action of the guanine analog, 5-amino-7-hydroxy-1 H - v -triazolo ( d ) pyrimidine, on a variety of experimental tumors has been reported. (aacrjournals.org)
  • In the review, the role of integrin receptors as well as of some of their ligands of the extracellular matrix in cases of parotid neoplasms is discussed, in particular, the data concerning the expression of various types of integrin adhesion molecules in benign and malignant tumors of the parotid, the expression of fibronectin, tenascin, and collagen type IV etc. (exp-oncology.com.ua)
  • The emerging focus on CSCs in brain tumors represents a paradigm shift in our understanding of the pathogenesis of these neoplasms. (springer.com)
  • Discussions focus on treatment and nature of relapse, cooperative study program, mammary and pituitary tumors, testicular interstitial cell tumors, and neoplasms of the female genital tract. (elsevier.com)
  • The present study shows the consistent pattern of the isozyme shift to the acidic adenylosuccinate synthase in rat experimental tumors, human hepatocellular carcinoma and colon adenocarcinoma. (springer.com)
  • Fibroepithelial neoplasms (or tumors ) are tumors with both epithelial and fibrous components. (wikidoc.org)
  • 44 patients had haematological neoplasms and 87 solid tumors. (greenmedinfo.com)
  • Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. (wikipedia.org)
  • G1 and G2 neuroendocrine neoplasms are called neuroendocrine tumors (NETs) - formerly called carcinoid tumours. (wikipedia.org)
  • Submit your Twitter account related to Liver Neoplasms, Experimental to be featured! (novusbio.com)
  • Submit your blog on Liver Neoplasms, Experimental to be featured! (novusbio.com)
  • The study of Liver Neoplasms, Experimental has been mentioned in research publications which can be found using our bioinformatics tool below. (novusbio.com)
  • These pathways complement our catalog of research reagents for the study of Liver Neoplasms, Experimental including antibodies and ELISA kits against GLUTATHIONE TRANSFERASE, GLUTATHIONE S-TRANSFERASE, GST-P, AFP, ALB. (novusbio.com)
  • Explore more on Liver Neoplasms, Experimental below! (novusbio.com)
  • We have 2511 products for the study of Liver Neoplasms, Experimental that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Chromatin Immunoprecipitation (ChIP), Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits. (novusbio.com)
  • Liver Neoplasms, Experimental is also known as Experimental Liver Neoplasms. (novusbio.com)
  • Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. (rupress.org)
  • In the experimental model, cells from the human small cell lung carcinoma cell line NCI-H69 cells were inoculated into the thoracic cavity of athymic mice and rats. (unt.edu)
  • When the analgesia response-dose curve (0-60 mg/kg) was studied, a significant decrease in the response in mice with experimental cancer versus control mice was observed. (curehunter.com)
  • Its content is based in part on the lecture outlines and selected histopathology laboratory components of an advanced course entitled The Pathobiology of Experimental Animal and Human Neoplasia, developed by me for the Experimental Pathology Curriculum of the Department of Pathology at the Medical College of Virginia. (springer.com)
  • Intraductal papillary mucinous neoplasm in chronic calcifying pancreatitis: egg or hen? (ox.ac.uk)
  • Intraductal papillary mucinous neoplasm (IPMN) is an increasingly reported entity. (ox.ac.uk)
  • Although some clinical and radiological features may predict malignancy presence in intraductal papillary mucinous pancreas neoplasms, preoperative diagnosis remains difficult. (biomedcentral.com)
  • In this study we present 7 patients with Intraductal Papillary Mucinous Neoplasm (IPMN) studied both with 18FDG-PET and magnetic resonance cholangiopancreatography (MRCP). (biomedcentral.com)
  • Within the whole group of cystic pancreas tumours, preoperative imaging, including magnetic resonance cholangiopancreatography (MRCP) and endoscopic ultrasound, usually allows three main lesions to be differentiated: serous adenoma, mucinous tumour and IPMN (intraductal papillary mucinous neoplasm) [ 2 ]. (biomedcentral.com)
  • Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. (amedeo.com)
  • Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). (plos.org)
  • Human Chromogranin A (CgA), a 439-residue-long protein present in the secretory granules of many normal and neoplastic neuroendocrine cells, currently represents the main biomarker for neuroendocrine neoplasms (NENs) [ 1 , 2 ]. (plos.org)
  • The management of small (≤20 mm), nonfunctioning pancreatic neuroendocrine neoplasms (pNENs) remains under debate. (nih.gov)
  • Even if the malignancy rate in sporadic, small pancreatic neuroendocrine neoplasms was lower than in large ones, this difference did not justify a watch-and-wait policy. (nih.gov)
  • The following grading scheme is currently recommended for all gastroenteropancreatic neuroendocrine neoplasms by the World Health Organization: If mitotic count and Ki-67 are discordant, the figure which gives the highest grade is used. (wikipedia.org)
  • Theresa L. Werner, M.D., is an associate professor in the Division of Oncology, Department of Medicine, at the University Of Utah School Of Medicine, an Investigator at the Huntsman Cancer Institute, and a member of the Experimental Therapeutics Program. (utah.edu)
  • Potentially malignant neoplasms include carcinoma in situ . (wikidoc.org)
  • This study tested a translational workflow for acquisition, expansion and testing of CRC-derived primary cultures of salivary gland neoplasms from patients presenting to an academic surgical practice. (biologists.org)
  • Procedures employed here illustrate an approach for reproducibly obtaining material for pathophysiological studies of salivary gland neoplasms, and other less common epithelial cancer types, that can be executed without compromising pathological examination of patient specimens. (biologists.org)
  • Primary salivary gland neoplasms arise from both major (parotid, submandibular or sublingual gland) and minor salivary glands ( Thompson, 2006 ). (biologists.org)
  • A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. (nih.gov)
  • In spite of convincing evidence of tumor inhibition, no regression of established neoplasms under therapy was observed, and the viability of inhibited cells was unimpaired, as indicated by their ability to reproduce normally on subsequent transplantation. (aacrjournals.org)
  • Methods in Hormone Research, Volume IV: Steroidal Activity in Experimental Animals and Man, Part B focuses on protection against irradiation damage, anti-mammary tumor activity, anti-androgens, steroids, and anti-progestational compounds. (elsevier.com)
  • This led to a controversy about whether diabetes mellitus itself or rather associated diseases, such as obesity or hepatitis C, are mainly responsible for tumor induction ( 11 , 16 , 17 ), and the need for experimental studies revealing the underlying mechanisms is emphasized ( 18 ). (aacrjournals.org)
  • Some sources consider a neoplasm to be synonymous with a tumor or unusual mass of tissue. (wikidoc.org)
  • An animal spinal tumor model is needed to better simulate the clinical situation and to allow percutaneous puncture, which may provide an experimental platform for the new nonvascular interventional therapies. (ajnr.org)
  • Mutations in the calreticulin gene (CALR) represented by deletions and insertions in exon 9 inducing a −1/+2 frameshift are associated with a significant fraction of myeloproliferative neoplasms (MPNs). (bloodjournal.org)
  • Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. (unboundmedicine.com)
  • The researchers examined genetically distinct single stem cells taken from patients with myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that are characterised by the over-production of mature blood cells together with an increased risk of both blood clots and leukaemia. (oregonbio.org)
  • Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. (rightdiagnosis.com)
  • Ikegami T., Natsumeda Y., Weber G. (1989) Isozyme Shift of Adenylosuccinate Synthase in Rat and Human Neoplasms. (springer.com)
  • Diagram illustrating benign neoplasms , namely fibroids of the uterus . (wikidoc.org)
  • Benign neoplasms include uterine fibroids and melanocytic nevi (skin moles). (wikidoc.org)
  • Hyperplasias and benign neoplasms. (omicsonline.org)
  • This second part of our review about vascular proliferations summarizes the clinicopathologic features of the cutaneous vascular hyperplasias and benign neoplasms. (omicsonline.org)
  • Benign neoplasms form a large group of hemangiomas with distinctive clinicopathologic characteristics, although some of them are of recent description and may produce diagnostic difficulties. (omicsonline.org)
  • Dr. Werner is heavily involved in clinical and translational research and is active in the experimental therapeutics and phase one clinical trial program. (utah.edu)
  • Home » Experimental Transplantation and Immunology Branch » Jennifer A. Kanakry, M.D. (cancer.gov)
  • It has been shown that combined high local hyperinsulinism and hyperglycemia after low-number islet transplantation into the livers of streptozotocin-diabetic rats lead to the development of hepatocellular neoplasms but a substantial cocarcinogenic effect of genotoxic streptozotocin could not be ruled out completely. (aacrjournals.org)
  • A focal hypermetabolism was documented in 2 patients (the standardized uptake value in the neoplastic foci was 6.7 and 9), while absence of FDG uptake in the neoplasm area was recorded in the remaining 5 cases. (biomedcentral.com)
  • For some types of neoplasm, e.g. lymphoma and leukemia , the demonstration of clonality is now considered to be necessary (though not sufficient) to define a cellular proliferation as neoplastic. (wikidoc.org)
  • This is an excellent textbook regarding the molecular and cell biology with respect to brain and spine neoplasms. (springer.com)
  • In 1966, Dr. Friend left Sloan-Kettering to become the first Director of the Center for Experimental Cell Biology and a Professor at the still developing Mount Sinai School of Medicine. (mssm.edu)
  • [email protected]#To investigate the relationship between the polymorphism of TET2 gene SNP rs3733609 and JAK2V617F allele burden in patients with myeloproliferative neoplasms (MPN). (bvsalud.org)
  • To explore the relationship between driver mutations and clinical characteristics in patients with Philadelphia chromosome ( Ph ) negative myeloproliferative neoplasms ( MPN ), so as to provide evidence for diagno-sis and treatment of the disease . (bvsalud.org)
  • In an exploratory phase-2 study patients with CIPN (NCI CTC grade 2/3) were randomized for WBV plus IP (experimental) to IP alone (standard). (greenmedinfo.com)
  • Fifteen (standard) and 22 (experimental) patients left the program due to progression/relapse or concomitant disease. (greenmedinfo.com)
  • This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). (cancer.gov)
  • Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? (amedeo.com)
  • Calreticulin mutants responsible for myeloproliferative neoplasms specifically activate the thrombopoietin receptor and in turn JAK2. (bloodjournal.org)
  • The rarity of these diseases and the lack of randomized trials mean that there is no consensus about optimal therapy for T- and NK-cell neoplasms. (exp-oncology.com.ua)
  • The total duration of pembrolizumab will be one year in the experimental arm. (cancer.gov)
  • Neoplasia ( new growth in Greek) is the abnormal proliferation of cells , resulting in a neoplasm . (wikidoc.org)
  • A neoplasm is an abnormal mass of tissue, the growth of which exceeds and is uncoordinated with that of the normal tissues, and persists in the same excessive manner after cessation of the stimulus which evoked the change. (wikidoc.org)
  • The mature or peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. (exp-oncology.com.ua)
  • Radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. (clinicaltrials.gov)
  • The purpose of this study was to evaluate the therapeutic efficacy of Re-188-RC-160 in experimental models of human small cell lung carcinomas which mimic the clinical presentation. (unt.edu)
  • Treatment of all T and NK neoplasms should be within the context of a clinical trial if possible as standard therapy gives disappointing results. (exp-oncology.com.ua)
  • All experimental animals receiving the gliosarcoma cells and not treated died within four weeks. (unt.edu)
  • The manuscript examines steroids in reactivated prostatic cancer and tumorigenesis in experimental animals. (elsevier.com)
  • However, parenteral and subcutaneous injections of supposedly significantly greater amounts of asbestos in experimental animals have produced neoplasms. (cdc.gov)
  • The experimental animals were inspected daily and occurring changes and symptoms recorded. (europa.eu)
  • Urinary creatine riboside can differentiate benign adrenal neoplasms from ACC. (aacrjournals.org)
  • By the next year, Dr. Friend had published her work in the Journal of Experimental Medicine, under the careful editing of Peyton Rous. (mssm.edu)